Frontier Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Frontier Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85M	Sell	740,866 -18,982	-2%	-$1.63M	0.79%	27
2026 Q1	$63.3M	Buy	759,848 +123,891	+19%	+$9.81M	0.65%	38
2025 Q4	$49.5M	Buy	635,957 +117,900	+23%	+$7.96M	0.53%	56
2025 Q3	$29.3M	Buy	518,057 +26,247	+5%	+$1.18M	0.26%	140
2025 Q2	$21.5M	Buy	491,810 +359,847	+273%	+$12.4M	0.2%	178
2025 Q1	$3.61M	Sell	131,963 -18,209	-12%	-$664K	0.04%	264
2024 Q4	$6.04M	Sell	150,172 -242,091	-62%	-$10.9M	0.06%	249
2024 Q3	$18.6M	Buy	+392,263	New	+$17.3M	0.17%	175

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Frontier Capital Management's KYMR Position: Q2 2026 in Review

Frontier Capital Management reduced its Kymera Therapeutics (KYMR) stake by 2.5% in Q2 2026, selling an estimated $1.63M and leaving 740,866 shares worth $85M. The position accounts for 0.79% of the portfolio, ranked #27.

Frontier Capital Management first reported a position in KYMR in Q3 2024 and has held it in 8 quarters since. 276 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Frontier Capital Management held 740,866 shares of Kymera Therapeutics worth $85M as of Q2 2026.
Frontier Capital Management sold 18,982 Kymera Therapeutics shares in Q2 2026, an estimated $1.63M.
Kymera Therapeutics made up 0.79% of Frontier Capital Management's portfolio in Q2 2026, its #27 holding.
Frontier Capital Management first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 8 quarters since.
276 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.